We’re teaming up with Quest Diagnostics to make our FDA-approved Shield™ blood-based screening test more accessible to patients across the U.S. With Quest’s network of 650,000+ clinical and hospital accounts, 6,000 in-office phlebotomists, and 2,000 patient service centers, physicians can seamlessly order Shield, and patients can complete screening with a simple blood draw. More details: https://lnkd.in/eQpEGiRw
Guardant Health
Biotechnology Research
Palo Alto, California 254,944 followers
Conquering Cancer With Data
About us
Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, we're transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant Health has commercially launched Guardant360® Liquid, Guardant360® CDx, Guardant360® Tissue, Guardant360 Response™, and Guardant Infinity™ tests for advanced-stage cancer patients, and Guardant Reveal® for early-stage cancer patients. The Guardant Health screening portfolio, including the FDA-approved Shield™ test, aims to address the needs of individuals eligible for cancer screening. Important Note for Job Applicants: Guardant Health is aware of recruiting scams where unauthorized individuals use the company's name in fraudulent emails, job postings, and social media messages. Please note that Guardant Health will never ask for money or credit card information during the job application process, nor does the company communicate with candidates via online chatrooms or personal email accounts such as Gmail or Hotmail.
- Website
-
https://guardanthealth.com/
External link for Guardant Health
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Palo Alto, California
- Type
- Public Company
Locations
Employees at Guardant Health
Updates
-
We’re proud to contribute to this effort led by Friends of Cancer Research. These results highlight the potential of ctDNA monitoring as an early indicator of treatment efficacy and demonstrate the impact of collective efforts in advancing cancer research.
New research led by Friends of Cancer Research shows that reductions in circulating tumor DNA (ctDNA) levels after treatment are associated with improved overall survival (OS) in patients with advanced non-small cell lung cancer (aNSCLC) treated with immunotherapy or chemotherapy. The analysis focused on different early ctDNA timepoints and definitions of molecular response (MR). Read the full publication: https://lnkd.in/evV74SFP. The aggregate analysis, published in the Journal for ImmunoTherapy of Cancer, analyzed data from four randomized clinical trials involving 918 patients treated with anti-PD(L)1 therapy (with or without chemotherapy) or chemotherapy alone. In patients receiving immunotherapy, ctDNA reductions at two early timepoints (i.e., up to 7 weeks and 7-13 weeks after treatment initiation) showed significant associations with improved OS across all MR thresholds (i.e., 50% decrease, 90% decrease, and 100% clearance). Among those treated with chemotherapy alone, these associations were more pronounced when assessing the 7–13-week timepoint. The majority of patients had the same category of molecular response at both timepoints. These findings support a growing body of evidence from Friends’ ctMoniTR Project. With additional studies planned, these findings bring us closer to a reliable early indicator of treatment efficacy, potentially transforming how we evaluate cancer therapies and accelerate drug development timelines. Thank you to the authors: Hillary Andrews, PhD, Nevine Zariffa, Katherine Nishimura, Yu (Yulia) Deng, Megan Eisele, Joe Ensor, Carin E., David Fabrizio, Emily Goren, Vincent Haddad, Minetta Liu, Dimple Modi, Achim Moesta, Katie Quinn, Adam Rosenthal, Diana Merino Vega, wei zou, Antje Hoering, Mark Stewart, Jeff Allen #ctDNAFriends #ctDNA
-
-
Moving from invasive procedures to a simple blood test—cancer care is entering a new era. At #WIREDHealth, our Co-CEO Helmy Eltoukhy sat down with WIRED to discuss how precision oncology and liquid biopsies are transforming detection, treatment decisions, and the patient experience. Watch the full conversation: https://lnkd.in/ermAYUkf
-
-
We’re proud to be a partner of the World Clinical Biomarkers & Companion Diagnostics Summit next week in Boston. Join our plenary session with Jean-Francois Martini to learn how our flexible, personalized solutions, combined with multimodal real-world data and global expertise, can streamline your clinical development program for success. Conference details: https://world-cdx.com/
-
-
Today we are proud to welcome Alex Azar to our board of directors. With senior leadership experience across government and the private sector, Secretary Azar brings a unique perspective on the intersection of policy, innovation, and patient access that will help us advance our mission to conquer cancer with data. More details: https://lnkd.in/etWP_kDM
-
-
Today, we announced a strategic agreement with LabFlorida/SunDx Labs to expand access to Shield™, our blood test for colorectal cancer screening, for older adults in senior living communities. Through this partnership, older adults across 20 states will be able to access Shield, helping millions stay up to date with their colorectal cancer screenings.
-
Guardant Health reposted this
The wireless revolution replaced landlines with mobile phones and gave rise to the app economy. In cancer care, however, we’re still relying on slow, expensive procedures developed decades ago. Liquid biopsies are changing that—replacing CT scans and surgical biopsies with a single blood test that can detect cancers at an early stage and accelerate treatments. The cofounder and CEO of Guardant Health, Helmy Eltoukhy, sits down with WIRED to discuss how precision oncology is reshaping the cancer patient experience and how liquid biopsies will soon be part of routine health care. WIRED Health
-
-
Today we’re excited to announce a new partnership with PathGroup to expand access to our FDA-approved Shield™ blood test for early cancer detection. Through PathGroup’s extensive network, Shield will soon be available in more than 250 hospitals and 15,000 physicians across 25 states, making it easier for millions of patients to access a convenient and pleasant screening option.
-
This Tuesday, our Co-CEO Helmy Eltoukhy will join WIRED at #WIREDHealth for a featured conversation: “Winning the War on Cancer." Just as the wireless revolution transformed communication, precision oncology is transforming cancer care. Helmy will explore how liquid biopsies are driving earlier detection, faster treatment decisions, and a more personalized patient experience. More details: https://lnkd.in/e3KvKNsa
-
-
At the European Alliance for Personalized Medicine (EAPM)'s VISION Europe 2030, our own Benjamin Gannon will join the policy panel “Innovation Without Access Is Failure” on September 3rd to discuss inequities in genomic testing and how to ensure inclusive coverage for all patients. Delivering genomic equity in Europe requires both innovation and pragmatism. Guardant’s ctDNA solutions, proven at scale, deployable locally, and validated in real-world European systems, show that equity is not only possible but achievable today. Watch the session live: https://lnkd.in/e2_PEA5a #VisionEurope2030
-